sec-butyl chloroformate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

3 (not reliable)

Rationale for reliability incl. deficiencies:

other: The different dilutions used in the study produced different LD 50 values. This may be due to hydrolysis or instability of the test substance in the emulsion applied. The study therefore is invalid because the concentration applied is unknown.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1970

Report date:

1970

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

Different doses of the test substance is applied i.p. to mice

GLP compliance:

no

Test material

Test material information

Constituent 1

Reference substance name:

sec-butyl chloroformate

EC Number:

241-475-6

EC Name:

sec-butyl chloroformate

Cas Number:

17462-58-7

Molecular formula:

C5H9ClO2

IUPAC Name:

butan-2-yl carbonochloridate

Constituent 2

Reference substance name:

sec. Butylchloroformate

IUPAC Name:

sec. Butylchloroformate

Constituent 3

Reference substance name:

XIX/353

IUPAC Name:

XIX/353

Details on test material:

- Name of test material (as cited in study report): sek. Butylchlorkohlensaeureester ( sec. butyl carbonochloridic acid ester)- Physical state: liquid - Analytical purity: ca. 95 % - Expiration date of the lot/batch: not reported - Stability under test conditions: not reported - Storage condition of test material: not reported

Test animals

Species:

mouse

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS - Source: Kisslegg, D - Weight at study initiation: mean male 27-39 g, mean female 24- 32 g no further information given ENVIRONMENTAL CONDITIONS not reported

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: aqueous emulsion with Traganth

Details on exposure:

Doses were administered in different concentrations in the vehicle: 12.5 to 50 mg/kg in 0.1%; 25-50 mg/kg in 0.5%, 100 mg/kg in 1%

Doses:

12.5, 16, 25, 50, 100 mg/kg

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days - Frequency of observations and weighing: Weighing was performed at the day of application, on day 7 after application and at the termination of the study. Clinical observations were done several times at day of application and once daily afterwards with the exception of weekends and holidays. - Necropsy of survivors performed: yes - Other examinations performed: clinical signs and mean body weight

Statistics:

none

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 50 mg/kg bw

Remarks on result:

other: when the test substance was administered in 0.1% concentration

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

< 25 mg/kg bw

Remarks on result:

other: when the test substance was administered in 0.5% concentration

Mortality:

No mortality observed in all doses up to 50 mg/kg when administered in 0.1% concentration.9/10 animals died in the 25 mg/kg dose group when administered in 0.5% concentration.All animals died in the 50 and 100 mg/kg dose group when administered in 0.5 and 1% concentration, respectively. Late deaths appeared in the 0.5% concentration treatments.

Clinical signs:

100 mg/kg, 50 and 25 mg/kg in 0.5%: directly after injection, high stepping gait with retarded movement of the extremities, gasping, piloerection, sunken flanks, abdominal position avoided. In the observation period abdominal position, gasping, ruffled fur, piloerection, adhering eye lids, slight apathy, sunken flanks; reversible after 14 d in the surviving animal.50 and 25 mg/kg in 0.1%: directly after injection, quiet behaviour, accelerated respiration, closed eye lids, after 4 h ruffled fur, gasping, closed eye lids. In the observation period abdominal position, gasping, ruffled fur, piloerection, adhering lids, slight apathy, adhering eye lids; reversible within 6 d.16 and 12.5 mg/kg in 0.1%: directly after injection accelerated respiration, partly gasping, partly closed eye lids, retarded movements of the extremities, stretching, sunken flanks. In the observation period, accelerated respiration, quiet behaviour, closed eye lids; reversible within 7 d.

Body weight:

not reported

Gross pathology:

Dead animals: intraabdominal adhesions, 1* vessel injected parts of the duodenumSacrificed animals: adehesions near the liver, 7*cyst fibrosis at the liver undersurface with adhesions there

Applicant's summary and conclusion

Executive summary:

The different dilutions used in the study produced different LD 50 values. This may be due to hydrolysis or instability of the test substance in the emulsion applied. The study therefore is invalid because the concentration applied is unknown.